Selected Characteristics of Studies Found in Clinical Trial Registers
| Register ID | Study register | Acronym | Disease | Clinical situation | Primary outcome | Patient-important primary outcome | First enrollment | Planned overall sample size |
| NCT00136864 | WHO/ct.gov | PET-START | NSCLC | Treatment planning | Upstaging | No | Aug 2004 | 400 |
| NCT00882609* | ct.gov | Cancer (breast, prostate, lung) | Unclear | Diagnostic performance | No | Jan 2009 | 550 | |
| NCT00265356 | WHO/ct.gov | PETCAM | CRC liver metastases | Staging/treatment planning | Change in management | No | Nov 2005 | 404 |
| NCT00976053* | ct.gov | CAD | Diagnostic (known CAD) | Diagnostic failure | No | June 2009 | 330 | |
| NCT00895349 | ct.gov | PET LACE | Cervical cancer | Treatment planning | Treatment delivered | No | Apr 2010 | 288 |
| NCT00964275 | ct.gov | Cancer | Primary diagnosis | Cancer diagnosed | No | Mar 2009 | 310 | |
| NCT00169598 | ct.gov | TEPELY | Lymphoma (HD, non-HD) | Unclear | Therapeutic prescription | No | Feb 2002 | 80 |
| NCT00199654 | ct.gov | CRC | Follow-up | Time to CRC relapse | (Yes) | Feb 2004 | 376 | |
| NCT01469026* | ct.gov | CUP Project | CUP | Staging | Detection of primary tumor possible | No | Nov 2011 | 220 |
| NCT00954148* | ct.gov | Cancer | Follow-up | 5-y survival, cost and time to identification of new disease | Yes | Sep 2009 | 53 | |
| NCT01170923 | ct.gov | NSCLC | Treatment planning | Change in response rate | (Yes) | Sep 2008 | 100 | |
| NCT00720070 | ct.gov | PET/CT | Head and neck cancer | Staging | Overall survival | Yes | Sep 2007 | 560 |
| NCT00433433 | ct.gov | Hodgkin lymphoma | Early response evaluation | Progression-free survival | Yes | Oct 2006 | 1,797 | |
| ACTRN12608000641392 | WHO | Prostate cancer | Treatment planning | Change in management | No | Oct 2008 | 100 | |
| ISRCTN49573946 | ISRCTN | BOOST | Lung cancer | Primary diagnosis/staging | Time to treatment decision | No | April 2008 | 168 |
↵* Studies not included in review by Scheibler et al. (10).
WHO = International Clinical Trials Registry (World Health Organization); ct.gov = clinicaltrials.gov; NSCLC = non–small cell lung cancer; CAD = coronary artery disease; HD = Hodgkin disease; CRC = colorectal cancer; CUP = cancer of unknown primary.
Parentheses around the words yes or no indicate an uncertain assessment.